Kalaris Therapeutics, Inc. (NASDAQ: KLRS), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, has announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell securities in a private placement for aggregate gross proceeds of approximately US$50 million, before deducting placement agent fees and other offering expenses.
Latham & Watkins represents the placements agents in the transaction with a Capital Markets team led by New York partners Nathan Ajiashvili and Alison Haggerty, with associates Jie Lin Nai and Elana Cates.
